Supplemental treatment of asthenia, functional.

Oral use

RESERVED FOR ADULTS AND CHILDREN OF MORE THAN 6 YEARS

Adult: 2 to 3 ampoules per day.

Child from 6 to 15 years: 1, bulb per day.

The contents of the ampoule should be diluted in a little water at the beginning of the meal.
Duration of treatment limited to 4 weeks.

AT ANTIASTHENIC SCREEN

(A: digestive system and metabolism).

Not applicable.

This medication is contraindicated in case of

· Hypersensitivity to any of the components of the solution, especially parabens

Hypercalcaemia, hypercalciuria, calcium lithiasis, tissue calcifications, due to the presence of calcium

· Genetic intolerance to fructose, due to the presence of sorbitol and sucrose

This drug is generally not recommended in combination with KAYEXALATE (see section Interactions with other medicinal products and other forms of interactions).
This medicinal product contains sorbitol and is not recommended for use in patients with fructose intolerance (rare hereditary disease)

This medicinal product contains sucrose. Its use is discouraged in patients with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase / isomaltase deficiency

In case of diabetes or hypoglucidic diet, take into account the amount of sucrose per ampoule: 2.65 g.
Consider the presence of 87 mg of calcium and 67 mg of phosphorus per ampoule.

This medication contains between 0.072 g and 0.079 g of alcohol per unit of intake.Use of this drug is dangerous in alcoholics and should be taken into account in pregnant or lactating women, children and , High-risk groups such as inadequate, hepatic or epileptic patients

This medicinal product contains methyl parahydroxybenzoate and may cause allergic reactions (possibly delayed).
Associations, deprecated

Related to the presence of sorbitol

KAYEXALATE (oral and rectal routes), risk of colonic necrosis, possibly fatal

Associations subject to precautions for use

Especially in case of association with vitamin D and because of the presence of calcium

Cyclines: decreased absorption, digestive cyclines. Take the calcium salts at a distance from the cyclins (more than 2 hours if possible).
Digital: risk of rhythm disorders. Clinical monitoring and, where appropriate, monitoring of ECG and serum calcium

Diphosphonates: risk of decreased digestive absorption of diphosphonates. Take the calcium salts away from the diphosphonates (more than 2 hours, if possible).

Associations to be taken into account

Thiazide diuretics: risk of hypercalcaemia by decreased elimination, urinary calcium

Not applicable.

No cases of overdose have been reported.

Pregnancy

There is no reliable evidence of teratogenesis in animals

In the clinic, no particular malformative or fetotoxic effect has appeared to date. However, the monitoring of pregnancies exposed to this drug is insufficient to exclude any risk.

Therefore, as a precautionary measure, it is preferable not to use this medication during pregnancy.


Due to the lack of data on the use of this medication in breast milk, the use of this medication should be avoided during breastfeeding.
Due to the presence of sorbitol, possibility of digestive disorders and diarrhea.

Supplemental treatment of asthenia, functional.